Review
One year in review 2016: pathogenesis of rheumatoid arthritis
E. Bellucci1, R. Terenzi2, G.M.C. La Paglia3, S. Gentileschi4, A. Tripoli5, C. Tani6, A. Alunno7
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Florence, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Florence, Italy. terenzi.ricca@gmail.com
- Rheumatology Unit, Department of Medicine, University of Perugia, Italy.
- Rheumatology Unit, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Medicine, University of Perugia, Italy.
CER9784
2016 Vol.34, N°5
PI 0793, PF 0801
Review
Free to view
(click on article PDF icon to read the article)
PMID: 27716458 [PubMed]
Received: 25/07/2016
Accepted : 01/09/2016
In Press: 16/09/2016
Published: 16/09/2016
Abstract
Rheumatoid arthritis (RA) is an autoimmune disease characterised by chronic synovial inflammation leading to joint destruction and bone erosions. Although the pathogenic mechanisms underlying the disease are not fully elucidated, it is known that genetic susceptibility and environmental factors trigger an abnormal autoimmune response. Potentially, any organ and tissue could be affected by RA and the increased cardiovascular (CV) risk represents the major complication responsible for a worse prognosis. In this setting, the shared pathogenic mechanisms between RA pathogenesis and accelerated atherosclerosis further strengthen the rationale for a treat-to-target strategy with synthetic and biologic disease modifying anti-rheumatic drugs. The aim of this review is to provide the novel insights, regarding the pathogenesis of RA, published over the last year.
